Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report
- 30 November 2003
- journal article
- case report
- Published by Elsevier in The Journal of Pediatrics
- Vol. 143 (5) , 674-677
- https://doi.org/10.1067/s0022-3476(03)00300-7
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Chimaeric anti‐CD20 monoclonal antibody (rituximab) in post‐transplant B‐lymphoproliferative disorder following stem cell transplantation in childrenBritish Journal of Haematology, 2001
- Mycophenolate mofetil for myasthenia gravis: An open-label pilot studyNeurology, 2001
- The Six Year Experience of Plasmapheresis in Patients with Myasthenia GravisTherapeutic Apheresis, 2000
- Acetylcholine receptors and myastheniaMuscle & Nerve, 2000
- Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patientsAnnals of Oncology, 2000
- High-dose intravenous immunoglobulin therapy in juvenile myasthenia gravisPediatric Neurology, 2000
- Myasthenia gravis: Immunological mechanisms and immunotherapyAnnals of Neurology, 1995
- Myasthenia GravisNew England Journal of Medicine, 1994
- Acetylcholine receptor antibodies in juvenile myasthenia gravisNeurology, 1993
- Myasthenia gravis in children: Long‐term follow‐upAnnals of Neurology, 1983